🚀 Owkin Launches K Pro at ESMO 2025! We’re unveiling K Pro – the first agentic AI co-pilot for biopharma powered by advanced biological reasoning models. K Pro is built on 10 years of Owkin’s AI innovation. It empowers pharma, biotech, and investors to make smarter, faster decisions across the R&D pipeline. K Pro combines: • Natural language interaction for querying complex biological questions • High-quality, multimodal biomedical data – curated, integrated, and AI-ready • Agentic AI that delivers, analysis, visualizations, and actionable clinical insights in moments, not months At its core, K Pro integrates OwkinZero - our pioneering biological large language model to perform high-level biological reasoning - and unifies fragmented workflows for both scientists and executives. Find the press release here: owkin.com/newsfeed/owkin-lau… 🔗 Visit us at ESMO booth #4021 to learn more about how K Pro is changing the game for biopharma decision-making or book a meeting with our team here: calendly.com/esmo-2025

Thank you @jpmorgan for hosting us at the European Healthcare Symposium in London during Tech Week. It was a fantastic opportunity for our CFO, Graeme Bell, and leadership team to engage with investors and share more about our vision at the intersection of AI and healthcare.

Last week, our executive committee visited our wet lab in Paris to see first-hand how Owkin is continuously validating our AI results in real world science. It was inspiring. Learn more about our approach → owkin.com/blogs-case-studies…

Our co-CEO Pascal Weinberger had the opportunity to speak with @BNPParibas to a select audience of business leaders on how AI is creating revenue across different sectors of the economy, how it is enabling efficiencies and how AI can improve sovereignty within countries.

Introducing K Pro’s KOL-certified skills. We’re working with leading scientists from our global KOL network, to distill their insights into skills usable in K Pro - to give you an expert angle on your scientific question. Find out more about K Pro → owkin.com/k-os/k-pro

🇫🇷 Deep dive into the new Sanofi x Owkin partnership in @Le_Figaro, covering the unique agentic infrastructure Owkin brings with K Pro and how it fits Sanofi’s strategic vision for AI - thank you Marie Bartnik for the detailed reporting. Read here (FR): lefigaro.fr/economie/sanofi-…

Today Owkin announces a multi-year strategic collaboration with @sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. Read the press release here: owkin.com/newsfeed/owkin-to-…

We're excited to participate in the inaugural Pulmonary Clinical Trials Workshop, where our CEO & Co-founder, @TClozel, will deliver the keynote lecture "Towards New Autopiloted Agentic Breakthroughs in Lung Diseases." Learn more about the workshop 👉 pctmeeting.com/

How is K Pro different from other AI Scientists? K Pro’s continuous improvement - based on patient data - and our insistence on real-world validation is explored in this article. Thanks @DrugTargetRev for the in-depth reporting. drugtargetreview.com/home/wh…

We’re excited to announce a clinical supply agreement with @BeOneMedicines to advance our INVOKE Phase 1a/1b trial of OKN4395 in advanced solid tumors. Read the press release: owkin.com/newsfeed/owkin-and…

We spoke with Yann Flereau, Co-founder & CEO of Blossom Lifesciences, about what turns hypotheses into biological truth. The hardest part isn’t generating ideas — it’s finding the right signal and having the data to validate it. That’s where rigorous validation matters most.

Over the past 3 weeks we shared a few notes on how we're building target ID into K Pro — and stress-testing it on our bladder cancer program. PR-AUC over ROC-AUC. Discovery Mode over hallmark recycling. 314 candidates → 1 ADC hit. Full blog: owkin.com/blogs-case-studies…

We sit down with our Chief Medical Officer, Dr. Caroline Hoffmann, to discuss her journey from surgical oncology to AI-powered biomedical research and why she believes clinicians need to play an active role in shaping the future of AI in medicine.

New on bioRxiv: We identify PRDX5 as a subtype-specific target in malignant pleural mesothelioma. ML-guided virtual screen of 3.6M compounds against cryptic allosteric pockets → 36 non-covalent hits, sub-µM inhibitors. 8% hit rate vs ~1% in typical HTS. biorxiv.org/content/10.64898…

📢 Announcing our new deal to build AI agents as part of a multi-year K Pro license agreement with @AstraZeneca Read the full press release here owkin.com/newsfeed/owkin-to-…

Peer-reviewed in BMC Medical Research Methodology: we benchmark 9 subgroup analysis methods for time-to-event RCTs. Interaction tests detect heterogeneity; ML-based CATE estimators identify good responders. link.springer.com/article/10…

"I think ultimately the whole conference should probably be about AI." — Pr. Jakob Kather at AACR 2026. Our recap of the meeting where foundation models, agentic systems, and the implementation gap took center stage: owkin.com/blogs-case-studies…

🎙️We sit down with our Chief Corporate Dev & Ops Strategy Officer @ Anna HD to get her take on Owkin’s mission with K Pro and how we work in an ecosystem alongside tech players such as Anthropic and OpenAI. Learn more about K Pro: owkin.com/k-os/k-pro

💊 AI scientists can now tackle drug R&D. What does that mean for pharma? Our Co-CEO Pascal Weinberger discusses how AI agents are transforming drug discovery, featured in @PharmaVoice. Read article here: pharmavoice.com/news/ai-phar… Learn about K Pro → owkin.com/k-os/k-pro

📢 Great to be highlighted at the AWS conference by Dan Sheeran last week - Dan foregrounded how: Book your demo of K Pro here -> owkin.com/connect/book-a-dem…

👀 In case you missed it on Friday - our CEO @TClozel has published this editorial in @FastCompany: why AI needs a reality check. 📰 Read it here fastcompany.com/91529003/ai-…